ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) has received a consensus broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three research analysts have rated the stock with a strong buy rating.

Brokerages have set a one year consensus price target of $14.00 for the company and are forecasting that the company will post ($0.74) EPS for the current quarter, according to Zacks. Zacks has also given ESSA Pharma an industry rank of 120 out of 255 based on the ratings given to its competitors.

EPIX has been the subject of a number of research analyst reports. Zacks Investment Research raised shares of ESSA Pharma from a “hold” rating to a “buy” rating and set a $4.25 target price for the company in a report on Thursday, May 10th. ValuEngine raised shares of ESSA Pharma from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

A hedge fund recently bought a new stake in ESSA Pharma stock. Omega Fund Management LLC acquired a new position in shares of ESSA Pharma Inc (NASDAQ:EPIX) (TSE:EPI) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 1,084,848 shares of the company’s stock, valued at approximately $4,122,000. ESSA Pharma makes up approximately 3.0% of Omega Fund Management LLC’s investment portfolio, making the stock its 9th largest position. Omega Fund Management LLC owned about 18.77% of ESSA Pharma as of its most recent SEC filing.

ESSA Pharma stock traded down $0.05 during mid-day trading on Monday, reaching $3.12. The company had a trading volume of 7,580 shares, compared to its average volume of 6,735. ESSA Pharma has a 1 year low of $2.00 and a 1 year high of $12.74. The company has a current ratio of 5.29, a quick ratio of 5.29 and a debt-to-equity ratio of 0.35. The stock has a market cap of $18.28 million, a PE ratio of -0.39 and a beta of 1.52.

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) last issued its earnings results on Monday, May 14th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.43). sell-side analysts forecast that ESSA Pharma will post -3.34 EPS for the current fiscal year.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.

Featured Story: Market Capitalization – What it Means for Investors

Get a free copy of the Zacks research report on ESSA Pharma (EPIX)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for ESSA Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ESSA Pharma and related companies with's FREE daily email newsletter.